

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



POSITIVE PROFIT ALERT AND INSIDE INFORMATION

This announcement is made by Modern Dental Group Limited (the “**Company**”, and together with its subsidiaries, collectively referred to as the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (the “**SFO**”) (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that, based on the preliminary assessment of the latest available unaudited consolidated management accounts of the Group (the “**Management Accounts**”) for the year ended 31 December 2025 (“**FY 2025**”), which have not been audited or reviewed by the auditor and/or the audit committee of the Group, the Group expects the following:

- (i) the revenue for FY 2025 is expected to be within the range of HK\$3,675 million to HK\$3,775 million, representing an increase within the range of approximately 9.2% to 12.2%, compared to the revenue for the year ended 31 December 2024 (“**FY 2024**”) of approximately HK\$3,364.0 million;
- (ii) the earnings before interest, taxes, depreciation and amortisation (“**EBITDA**”) for FY 2025 is expected to be within the range of HK\$920 million to HK\$950 million, representing an increase within the range of approximately 29.8% to 34.0%, compared to the EBITDA for FY 2024 of approximately HK\$708.8 million; and
- (iii) the net profit for FY 2025 is expected to be within the range of HK\$590 million to HK\$610 million, representing an increase within the range of approximately 45.0% to 49.9%, compared with a net profit for FY 2024 of approximately HK\$406.9 million.

The increase in the revenue was due to the continued organic growth of the Group (mainly in Europe and Australia regions) and accelerated by our acquisition of Hexa Ceram Company Limited (“**Hexa Ceram**”), Thailand’s largest dental laboratory, which was completed in January 2025.

The increase in the EBITDA and the net profit was predominately due to:

- (i) the continued improvement in operational efficiency as a result of an increase in the proportion of digital solution cases;
- (ii) favourable foreign currency movements from January to December 2025, including the appreciation of the Euro against Renminbi and Hong Kong dollars; and
- (iii) the profit contributions from acquisitions of Hexa Ceram and Digital Sleep Design Pty Limited.

The Company is currently finalising the consolidated financial results of the Group for FY 2025. The information contained in this announcement is only based on the information currently available to the Company and the preliminary assessment of the Board on the management accounts prepared in accordance with the International Financial Reporting Standards applicable for FY 2025, which have not been audited or reviewed by the auditors and/or the audit committee of the Company. The final consolidated results of the Group for FY 2025 is expected to be announced by the end of March 2026, which may be different from the figures and information contained in this announcement.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Modern Dental Group Limited
Chan Ronald Yik Long
Chairman and Chief Executive Officer

Hong Kong, 16 March 2026

As at the date of this announcement, the board of directors of the Company comprises Chan Ronald Yik Long, Chan Yik Yu, Chan Kwun Pan, and Chan Chi Yuen, as executive Directors, Chan Kwun Fung, as non-executive Director, and Cheung Wai Bun Charles J.P., Chan Yue Kwong Michael and Yau Ka Po as independent non-executive Directors.